Subtype
Adrenal Gland Neoplasm
CI-CAN-00000413Explore in graph →
Non-malignant54 active trials1 approved drugs4 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000413Explore in graph →
Clinical trials
262 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01377532 | Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma | approved for marketing | — | — | University of California, San FranciscoOTHER | 1 | May 6, 2020 | clinicaltrials |
| NCT02961491 | Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma | approved for marketing | — | — | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 30, 2019 |
| clinicaltrials |
Data updated 22 days agoSource updated May 6, 2020source: clinicaltrials